Trace glucose and lipid metabolism in high androgen and high-fat diet induced polycystic ovary syndrome rats

Reproductive Biology and Endocrinology

Ying-Li Lu¹  Yi Chen¹  Fang-Zhen Xia¹  Pan Weng¹  Hui Xu¹  Hui Wu¹  Hua-Ling Zhai¹ 

[1] Endocrinology and Metabolism Research Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital Affiliated Shanghai Jiaotong University School of Medicine, Shanghai 200011, China

关键词: Polycystic ovary syndrome;    High-fat diet;    Lipid metabolism;    Glucose metabolism;    Andronate;   

Others  :  1151036
DOI  :  10.1186/1477-7827-10-5

 received in 2011-10-29, accepted in 2012-01-25,  发布年份 2012

【 摘 要 】

Background

There is a high prevalence of diabetes mellitus (DM) and dyslipidemia in women with polycystic ovary syndrome (PCOS). The purpose of this study was to investigate the role of different metabolic pathways in the development of diabetes mellitus in high-androgen female mice fed with a high-fat diet.

Methods

Female Sprague-Dawley rats were divided into 3 groups: the control group(C), n = 10; the andronate-treated group (Andronate), n = 10 (treated with andronate, 1 mg/100 g body weight/day for 8 weeks); and the andronate-treated and high-fat diet group (Andronate+HFD), n = 10. The rate of glucose appearance (Ra of glucose), gluconeogenesis (GNG), and the rate of glycerol appearance (Ra of glycerol) were assessed with a stable isotope tracer. The serum sex hormone levels, insulin levels, glucose concentration, and the lipid profile were also measured.

Results

Compared with control group, both andronate-treated groups exhibited obesity with higher insulin concentrations (P < 0.05) but similar blood glucose concentrations. Of the two andronate-treated groups, the andronate+HFD group had the most serious insulin resistance (IR). Estrus cycles were completely acyclic, with polycystic ovaries and elevated serum lipid profiles in the andronate+HFD group (P < 0.05). Ra of glucose and GNG increased significantly in the andronate+HFD rats. However, the Ra of glycerol was similar in the three groups.

Conclusions

Andronate with HFD rat model showed ovarian and metabolic features of PCOS, significant increase in glucose Ra, GNG, and lipid profiles, as well as normal blood glucose levels. Therefore, aberrant IR, increased glucose Ra, GNG, and lipid metabolism may represent the early-stage of glucose and lipid kinetics disorder, thereby might be used as potential early-stage treatment targets for PCOS.

【 授权许可】

   
2012 Zhai et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Ehrmann DA: Polycystic ovary syndrome. N Engl J Med 2005, 352(12):1223-1236.
• [2]Norman RJ, Dewailly D, Legro RS, Hickey TE: Polycystic ovary syndrome. Lancet 2007, 370:685-697.
• [3]Barber TM, McCarthy MI, Wass JA, Franks S: Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006, 65:137-145.
• [4]Nelson VL, Qin K-N, Rosenfield RL, Wood JR, Penning TM, Legro RS, Strauss JF, McAllister JM: The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86:5925-5933.
• [5]Soule SG: Neuroendocrinology of the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 1996, 10(2):205-219.
• [6]Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84(1):165-169.
• [7]Dunaif A, Finegood DT: Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81(3):942-947.
• [8]Acién P, Quereda F, Matallín P, Villarroya E, López-Fernández JA, Acién M, Mauri M, Alfayate R: Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999, 72:32-40.
• [9]Traub ML: Assessing and treating insulin resistance in women with polycystic ovarian syndrome. World J Diabetes 2011, 2(3):33-40.
• [10]Radavelli-Bagatini S, Blair AR, Proietto J, Spritzer PM, Andrikopoulos S: The New Zealand obese mouse model of obesity insulin resistance and poor breeding performance: evaluation of ovarian structure and function. J Endocrinol 2011, 209(3):307-315.
• [11]El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A: Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010, 109:239-241.
• [12]Bouglé D, Zunquin G, Sesbouë B, Sabatier JP: Relationships of cardiorespiratory fitness with metabolic risk factors, inflammation, and liver transaminases in overweight youths. Int J Pediatr 2010, 2010:1-5.
• [13]Lu YL, Jiang BR, Xia FZ, Zhai HL, Chen Y, Yu J, Zhao LJ, Wang NJ, Qiao J, Yang LZ: Changes of pituitary and penile structure in male adult rats following castration and high-fat diet. J Endocrinol Invest 2011, 34(2):111-116.
• [14]Freeman R, Pollack R, Rosenbloom E: Assessing impaired glucose tolerance and insulin resistance in Polycystic Ovarian Syndrome with a muffin test: alternative to glucose tolerance test. Endocr Pract 2010, 16(5):810-817.
• [15]American Diabetes Association: Consensus development conference on insulin resistance. Diabetes Care 1998, 21:310-314.
• [16]Baptiste CG, Battista MC, Trottier A, Baillargeon JP: Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2010, 122:42-52.
• [17]Pesant MH, Baillargeon JP: Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril 2011, 95:210-215.
• [18]Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nakama Y, Kagawa E, Dai K, Ootani T, Ikenaga H, Morimoto Y, Ejiri K, Oda N: Glucometabolic responses during glucose tolerance test: a comparison between known diabetes and newly detected diabetes after acute myocardial infarction. Int J Cardiol 2011, 152(1):78-82.
• [19]Manni L, Cajander S, Lundeberg T, Naylor AS, Aloe L, Holmäng A, Jonsdottir IH, Stener-Victorin E: Effect of exercise on ovarian morphology and expression of nerve growth factor and alpha(1)- and beta(2)-adrenergic receptors in rats with steroid-induced polycystic ovaries. J Neuroendocrinol 2005, 17(12):846-858.
• [20]Kafali H, Iriadam M, Ozardali I, Demir N: Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res 2004, 35(2):103-108.
• [21]Mannerås L, Cajander S, Holmäng A, Seleskovic Z, Lystig T, Lönn M, Stener-Victorin E: A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 2007, 148(8):3781-3791.
• [22]Minassian C, Tarpin S, Mithieux G: Role of Glucose-6 Phosphatase, Glucokinase, and Glucose-6 Phosphate in Liver Insulin Resistance and Its Correction by Metformin. Biochem Pharmacol 1998, 55:1213-1219.
• [23]Acién P, Quereda F, Matallín P, Villarroya E, López-Fernández JA, Acién M, Mauri M, Alfayate R: Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999, 72:32-40.
• [24]Luque-Ramírez M, Alpañés M, Escobar-Morreale HF: The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism. Fertil Steril 2010, 94:2214-2221.
• [25]Coviello AD, Legro RS, Dunaif A: Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006, 91:492-497.
• [26]Ding EL, Song Y, Malik VS, Liu S: Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295:1288-1299.
• [27]Padmanabhan V, Veiga-Lopez A, Abbott DH, Recabarren SE, Herkimer C: Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology 2010, 151:595-605.